Cybin Stock Price, News & Analysis
Why is HELP Stock Up Today?
Company Description
Cybin (NASDAQ: HELP) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $274.4M, ranking #4,257 among all listed U.S. companies by market cap.
HELP stock has declined 27.4% over the past year, placing it at #4,026 in year-to-date performance among tracked companies. Shares last traded at $5.61.
This page provides a comprehensive overview of HELP stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Cybin (HELP) stock last traded at $5.61, up 3.64% from the previous close. Over the past 12 months, the stock has lost 27.4%. At a market capitalization of $274.4M, HELP is classified as a micro-cap stock with approximately 50.0M shares outstanding.
HELP Rankings
Latest News
Cybin has 10 recent news articles, with the latest published today. Of the recent coverage, 4 articles coincided with positive price movement and 2 with negative movement. Key topics include management, clinical trial, earnings. View all HELP news →
SEC Filings
Cybin has filed 5 recent SEC filings, including 3 Form 6-K, 2 Form SCHEDULE 13G. The most recent filing was submitted on April 20, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all HELP SEC filings →
Financial Highlights
Upcoming Events
Phase 3 HLP003 topline
APPROACH topline readout
Topline Phase 3 data HLP003
Cybin has 3 upcoming scheduled events. The next event, "Phase 3 HLP003 topline", is scheduled for October 1, 2026 (in 163 days). Investors can track these dates to stay informed about potential catalysts that may affect the HELP stock price.
Short Interest History
Short interest in Cybin (HELP) currently stands at 3.4 million shares, down 3.3% from the previous reporting period, representing 8.0% of the float. Over the past 12 months, short interest has increased by 11.6%.
Days to Cover History
Days to cover for Cybin (HELP) currently stands at 4.9 days, up 143.5% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The ratio has shown significant volatility over the period, ranging from 2.0 to 9.8 days.
HELP Company Profile & Sector Positioning
Cybin (HELP) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ. In monthly performance, the stock ranks #1,172 among all tracked companies.
Helus Pharma (Nasdaq: HELP) announced a management change on April 20, 2026: CEO Michael Cola stepped down effective immediately and Co-founder and Executive Chairman Eric So will resume as Interim CEO while the Board conducts a search for a permanent successor.
The company said priorities remain advancing the clinical pipeline, including the APPROACH trial topline readout for HLP003 expected in the fourth quarter, and ensuring continuity of leadership during the transition.